Induced expression of selected plant defence related genes in pot azalea, <Emphasis Type="Italic">Rhododendron simsii</Emphasis> hybrid

A set of putative marker genes to study plant defense responses against Polyphagotarsonemus latus, a key pest in the production of Rhododendron simsii hybrids, was selected and validated. Genes belonged to the biosynthetic pathway of phytohormones jasmonic acid (JA) (RsLOX, RsAOS, RsAOC, RsOPR3 and RsJMT) and salicylic acid (SA) (RsPAL and RsICS). Furthermore, RsPPO, a putative marker gene for oxidative stress response was successfully cloned from R. simsii. A CTAB-based extraction protocol was optimized to assure excellent RNA quality for subsequent RT-qPCR analysis. The RT-qPCR protocol was extensively tested and RsRG7 and RsRG14 were selected as reference genes from a geNorm pilot study. Validation of the marker genes was done after application with elicitors [methyl jasmonate (MeJA), coronatine, β-aminobutyric acid and acibenzolar-Smethyl] or wounding. Both 100 μM MeJA and 0.1 μM coronatine had a significant effect on the expression of all marker genes. Foliar application of MeJA on the shoots resulted in a significantly earlier response when compared to root application and subsequent sampling of the shoots. Expression patterns after MeJA treatment were generally the same in six R. simsii genotypes: ‘Nordlicht’, ‘Elien’, ‘Aiko Pink’, ‘Michelle Marie’, ‘Mevrouw Gerard Kint’ and ‘Sachsenstern’. Wounding resulted in the same expression patterns as MeJA treatment except for RsJMT. None of the genotypes showed a significant induction of the latter gene 6 h upon wounding. Findings of these experiments indicated that the tolerant genotype ‘Elien’ has low basal expression levels of RsPPO. This might be the first step towards the breeding of mite-tolerant genotypes.     

Top 20 environmental weeds for classical biological control in Europe: a review of opportunities, regulations and other barriers to adoption

Classical biological control remains the only tool available for permanent ecological and economic management of invasive alien species that flourish through absence of their co‐evolved natural enemies. As such, this approach is recognized as a key tool for alien species management by the Convention on Biological Diversity (CBD), the European and Mediterranean Plant Protection Organization (EPPO) and the European Strategy on Invasive Alien Species (ESIAS). Successful classical biological control programmes abound around the world, despite disproportionate attention being given to occasional and predictable non‐target impacts. Despite more than 130 case histories in Europe against insect pests, no exotic classical biological control agent has been released in the EU against an alien invasive weed. This dearth has occurred in the face of increasing numbers of exotic invasive plants being imported and taking over National Parks, forests and amenity areas in this region, as well as a global increase in the use of classical biological control around the world. This paper reviews potential European weed targets for classical biological control from ecological and socioeconomic perspectives using the criteria of historical biological control success, taxonomic isolation from European native flora, likely availability of biological control agents, invasiveness outside Europe and value to primary industry and horticulture (potential for conflicts of interest). We also review why classical biological control of European exotic plants remains untested, considering problems of funding and public perception. Finally, we consider the regulatory framework that surrounds such biological control activities within constituent countries of the EU to suggest how this approach may be adopted in the future for managing invasive exotic weeds in Europe.     

Chronic progressive lymphoedema in draught horses

The objective of this review was to summarise and evaluate the current state of knowledge about chronic progressive lymphoedema in draught horses. Clinical signs of this multifactorial disorder are mainly restricted to the lower limbs, comprising progressively deteriorating skin, swelling and deformation. Although typical lesions were first reported at the beginning of the 20th century, chronic progressive lymphoedema was recognised as a specific syndrome only in 2003, and since then research has driven forward. Despite the high prevalence in some breeds and the serious economic impact, the pathogenesis is not fully understood, and the available treatment options remain symptomatic and noncurative. There is a need to improve diagnostic techniques and to develop selection tools.     

Genetic parameters for chronic progressive lymphedema in Belgian Draught Horses

Genetic parameters for chronic progressive lymphedema (CPL)‐associated traits in Belgian Draught Horses were estimated, using a multitrait animal model. Clinical scores of CPL in the four limbs/horse (CPL_clin), skinfold thickness and hair samples (hair diameter) were studied. Due to CPL_clin uncertainty in younger horses (progressive CPL character), a restricted data set (D_3+) was formed, excluding records from horses under 3 years from the complete data set (D_full). Age, gender, coat colour and limb hair pigmentation were included as fixed, permanent environment and date of recording as random effects. Higher CPL_clin certainty (D_3+) increased heritability coefficients of, and genetic correlations between traits, with CPL_clin heritabilities (SE) for the respective data sets: 0.11 (0.06) and 0.26 (0.05). A large proportion of the CPL_clin variance was attributed to the permanent environmental effect in D_full, but less in D_3+. Date of recording explained a proportion of variance from 0.09 ± 0.03 to 0.61 ± 0.08. Additive genetic correlations between CPL_clin and both skinfold thickness and hair diameter showed the latter two traits cannot be used as a direct diagnostic aid for CPL. Due to the relatively low heritability of CPL_clin, selection should focus on estimated breeding values (from repeated clinical examinations) to reduce CPL occurrence in the Belgian Draught Horse.     

Conception rates in European fallow does (Dama dama dama) following intrauterine insemination with frozen-thawed semen from Mesopotamian fallow (Dama dama mesopotamica) and crossbred (Dama dama dama x Dama dama mesopotamica) bucks

Ninety eight parous fallow does received laparoscopic intrauterine insemination of frozen-thawed semen at one of 2 fixed intervals following oestrus synchronisation treatment. Semen was collected from a Mesopotamian (Dama dama mesopotamica) and a crossbred (F1) (Dama dama dama x Dama dama mesopotamica) fallow buck. Does were inseminated at either 56 or 66 hours after the removal of an intravaginal controlled internal drug releasing device. Eighty eight does received a single straw of frozen-thawed semen containing a total of 50 x 10(6) spermatozoa, while the remaining 10 received split straws containing 25 x 10(6) spermatozoa. Overall, the use of F1 semen containing 50 x 10(6) spermatozoa resulted in a 68% (17/25) conception rate compared with the Mesopotamian semen, which resulted in a 41% (26/63) conception rate. Conceptions were also achieved using 25 x 10(6) spermatozoa of either Mesopotamian or F1 semen (3/8 versus 2/2, respectively). Overall, the conception rate was higher for F1 than Mesopotamian semen (P less than 0.025) and there was a significant interaction with time of insemination (P less than 0.05); for F1 semen there was no difference in conception rate at the 2 insemination times, but for Mesopotamian semen conception was significantly higher (P less than 0.005) following insemination at 66 hours than at 56 hours.     

Effects of Saccharomyces cerevisiae subspecies boulardii CNCM I-1079 on feed intake by healthy beef cattle treated with florfenicol and on health and performance of newly received beef heifers

The effects of a live yeast supplement [Saccharomyces cerevisiae subspecies boulardii CNCM I-1079; ProTernative Stress Formula (PTSF) yeast, Ivy Natural Solutions, Overland Park, KS] on DMI, performance, and health of beef cattle were evaluated in 3 experiments. In Exp. 1, a pilot study was conducted with 10 healthy beef steers fed a 65% concentrate diet to evaluate the effects of florfenicol (s.c. in the neck vs. sterile water injection) on DMI. Steers injected with florfenicol had 15.6 (P = 0.092) and 22.2% (P = 0.015) decreases in DMI compared with controls on the day of and day after injection, respectively, with no differences for the remainder of the 7-d period. In the main study of Exp. 1, healthy beef steers (6 pens of 5 steers each/treatment) were fed the control or PTSF yeast diets (0.5 g of yeast x steer(-1) x d(-1)) for 5 d before being injected s.c. with florfenicol. Compared with the 5 d before injection, DMI decreased after injection, but it did not differ (P > 0.66) between treatments on the day of and day after injection. By the second day after injection, DMI tended (P = 0.107) to increase for steers fed PTSF yeast vs. control steers, with a trend for a similar pattern on the third day after injection (P = 0.197). No differences were noted between treatments for the remainder of the 7-d period or for the subsequent 2 wk. In Exp. 2, 3 loads of beef heifers (277 heifers; average initial BW = 230.3 kg) were shipped from auction barns and assigned randomly to 1 of 2 treatments (5 pens/treatment in each load) during 35-d receiving periods: 1) control = 65% concentrate receiving diet; or 2) PTSF yeast = 65% concentrate receiving diet with PTSF yeast added to supply 0.5 g of yeast x heifer(-1) x d(-1). All heifers were treated with florfenicol on arrival, and PTSF yeast heifers received approximately 1 g of yeast via an oral paste at the time of processing. Averaged over the 3 loads, treatments did not affect (P > or = 0.12) DMI, ADG, or G:F during the 35-d period, but the percentage of cattle treated once or more for bovine respiratory disease (BRD) was greater for control (P = 0.04) than for PTSF yeast heifers (24.0 vs. 13.78% respectively). In Exp. 3, 2 loads of beef heifers (180 heifers; average initial BW = 209.0 kg) that were not treated with antibiotic at the time of arrival processing were fed a 70% concentrate receiving diet and assigned the same 2 treatments as in Exp. 2. No differences (P > 0.72) were noted between treatments in ADG, DMI, and G:F for the 35-d receiving period, and BRD morbidity pooled across loads did not differ between treatments (40.2 vs. 33.1% for control vs. PTSF yeast). Providing PTSF yeast in an oral paste at the time of processing combined with the addition of 0.5 g of yeast x animal(-1) x d(-1) in the diet had little effect on receiving period performance; however, it decreased BRD morbidity in heifers given florfenicol on arrival but was without effect on BRD morbidity in heifers that did not receive a prophylactic antibiotic.